Capstone Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Capstone Therapeutics's estimated annual revenue is currently $1.6M per year.
- Capstone Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Capstone Therapeutics has 10 Employees.
- Capstone Therapeutics grew their employee count by 0% last year.
Capstone Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.8M | 5 | 0% | N/A | N/A |
#2 | $0.9M | 6 | 0% | N/A | N/A |
#3 | $0.8M | 5 | -29% | N/A | N/A |
#4 | $5.3M | 34 | 0% | N/A | N/A |
#5 | $2.5M | 16 | -20% | N/A | N/A |
#6 | $1.1M | 7 | 0% | N/A | N/A |
#7 | $0.9M | 6 | 0% | N/A | N/A |
#8 | $2.2M | 29 | 21% | $58.2M | N/A |
#9 | $171.9M | 1109 | -3% | N/A | N/A |
#10 | $0.9M | 6 | 0% | N/A | N/A |
What Is Capstone Therapeutics?
Capstone Therapeutics (OTCQB: CAPS) is a clinical stage biotechnology company developing a family of new peptide drugs to serve cardiovascular patients with high cholesterol and triglyceride levels otherwise unaddressable through standard therapy. Capstone holds an FDA Orphan drug designation for its lead molecule, AEM-28, for Homozygous Familial Hypercholesterolemia (HoFH) and may also target indications in acute coronary syndrome, peripheral artery disease and type 2 diabetes.
keywords:N/A
N/A
Total Funding
10
Number of Employees
$1.6M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Tempe
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.8M | 10 | -23% | N/A |
#2 | $2M | 10 | -50% | N/A |
#3 | $1.5M | 10 | -62% | N/A |
#4 | $1.8M | 10 | -68% | N/A |
#5 | $0.9M | 10 | 0% | N/A |